Albert Qin

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Replacement Therapy

Top Venues

British journal of clinical pharmacology

International journal of molecular sciences

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Albert Qin, Daoxiang Wu, Yaning Li, Jingjing Zhang, Wei Wang, Weihong Shen, Jason Liao, Sheena Lin, Cynthia Chang, Haoqi Chen, Jie Cui, Xia Su
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. British journal of clinical pharmacology 90 (6) (2024)
David Wang, Natalie Hughes-Medlicott, Lilian Klingler, Yi Wang, Noelyn Hung, Stephen Duffull, Tak Hung, Paul Glue, Albert Qin, Rudolf Kwan, Wing-Kai Chan, Christopher Jackson
A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study. Pharmaceutics 16 (5) (2024)
Albert Qin, Daoxiang Wu, Yaning Li, Jingjing Zhang, Wei Wang, Weihong Shen, Jason Liao, Sheena Lin, Cynthia Chang, Haoqi Chen, Jie Cui, Xia Su
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. British journal of clinical pharmacology 90 (6) (2024)
David Wang, Natalie Hughes-Medlicott, Lilian Klingler, Yi Wang, Noelyn Hung, Stephen Duffull, Tak Hung, Paul Glue, Albert Qin, Rudolf Kwan, Wing-Kai Chan, Christopher Jackson
A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study. Pharmaceutics 16 (5) (2024)
Xu Xu, Shih-Long Yan, Yi-Te Yo, Peiyu Chiang, Chan-Yen Tsai, Lih-Ling Lin, Albert Qin
A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer. Cancers 16 (17) (2024)
Albert Qin, Daoxiang Wu, Yaning Li, Jingjing Zhang, Wei Wang, Weihong Shen, Jason Liao, Sheena Lin, Cynthia Chang, Haoqi Chen, Jie Cui, Xia Su
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. British journal of clinical pharmacology (2024)
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G C A Jackson, Noelyn Hung, Jianguo Zhi, David L Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. Therapeutic advances in medical oncology 15 (2023)
Albert Qin, Chang-Ru Wu, Ming-Chih Ho, Chan-Yen Tsai, Pei-Jer Chen
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results. International journal of molecular sciences 25 (1) (2023)
Albert Qin, Chang-Ru Wu, Ming-Chih Ho, Chan-Yen Tsai, Pei-Jer Chen
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results. International journal of molecular sciences 25 (1) (2023)
Jie Jin, Albert Qin, Lei Zhang, Weihong Shen, Wei Wang, Jingjing Zhang, Yaning Li, Daoxiang Wu, Zhijian Xiao
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera. Future oncology (London, England) (2023)
Albert Qin, Chang-Ru Wu, Ming-Chih Ho, Chan-Yen Tsai, Pei-Jer Chen
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results. International journal of molecular sciences 25 (1) (2023)
Jin-Bon Hong, Po-Yuan Wu, Albert Qin, Yi-Wen Huang, Kuan-Chiao Tseng, Ching-Yu Lai, Wing-Kai Chan, Jane Fang, David L Cutler, Tsen Fang Tsai
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics 14 (10) (2022)